Melinta Therapeutics announces Board member John Johnson as CEO

– USA, CT – Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company developing and commercializing novel antibiotics to treat serious bacterial infections, today announced that John H. Johnson has agreed to become the permanent chief executive officer of Melinta, subject to the terms of an employment contract and the close of the previously announced commitment for a credit facility of up to $135 million from Vatera Healthcare Partners LLC. Mr. Johnson is a director of Melinta and has served as interim CEO of the Company since October 22, 2018.

“John is a biopharmaceutical industry leader with a proven track record of growing businesses and unlocking value, and we are confident that he is the right person to lead Melinta into its next phase of growth and development,” said Kevin T. Ferro, chairman of Melinta Therapeutics. “During John’s brief tenure as interim CEO, he has moved decisively and with urgency to further advance the Company’s mission to provide life-saving therapeutic solutions that address the evolving global threat of bacterial infections and antibiotic resistance. On behalf of the Board, we look forward to continuing to benefit from John’s leadership and antibiotic therapeutic expertise as we continue working to reposition Melinta and increase value for our shareholders.”

About John H. Johnson

John H. Johnson has more than 30 years of biopharmaceutical industry, executive leadership and commercial experience at leading global organizations, including Johnson & Johnson, Eli Lilly & Company, ImClone and Pfizer, Inc. In addition to Melinta, Mr. Johnson currently serves on the boards of Aveo Oncology, Histogenics Corporation, Portola Pharmaceuticals, Inc., and is chairman of Strongbridge Biopharma plc. Mr. Johnson previously served as a director at Cempra and Sucampo. He also previously served as president and chief executive officer of Dendreon Corporation from February 2012, became chairman in July 2013, and served as chairman until June 2014 and president and chief executive officer until August 2014. Prior to this role, Mr. Johnson served as president of Eli Lilly & Company’s Global Oncology Unit following the company’s 2008 acquisition of ImClone Systems Incorporated, where he served as chief executive officer and on ImClone’s board. Prior to ImClone, Mr. Johnson served as the company group chairman of biopharmaceuticals within Johnson & Johnson, where he was responsible for biotechnology, immunology and oncology commercial business units. Prior to that role, he held several executive positions at Johnson & Johnson, Parkstone Medical Information Systems, Inc., Ortho-McNeil Pharmaceutical Corporation and Pfizer Inc. While at Ortho-McNeil, Mr. Johnson was responsible for the company’s anti-infectives portfolio. During his career, Mr. Johnson also served as a member of the board of directors of Pharmaceutical Research and Manufacturers of America (PhRMA), the Health Section Governing Board of Biotechnology Industry Organizations (BIO), and BioNJ.

“We will continue to take the necessary actions in order to lower costs across the organization, accelerate sales growth of our commercial products, Baxdela (delafloxacin), Vabomere (meropenem and vaborbactam), Orbactiv (oritavancin), and Minocin (minocycline) for Injection, while strengthening the Company’s financial position. The commitment for the new credit facility we announced today with Vatera is an important milestone that we believe will increase our financial flexibility and position us to build on the growing momentum in our business. I look forward to continuing to work closely with the Board, management team and all of our talented employees to deliver anti-infective solutions to patients while driving further growth and value creation for Melinta and its shareholders,” said John H. Johnson, interim CEO and director of Melinta.

About Melinta Therapeutics

Melinta Therapeutics, Inc. is the largest pure-play antibiotics company, dedicated to saving lives threatened by the global public health crisis of bacterial infections through the development and commercialization of novel antibiotics that provide new therapeutic solutions. Its four marketed products include Baxdela (delafloxacin), Vabomere (meropenem and vaborbactam), Orbactiv (oritavancin), and Minocin (minocycline) for Injection. This portfolio provides Melinta with the unique ability to provide providers and patients with a range of solutions that can meet the tremendous need for novel antibiotics treating serious infections.

For more information : https://www.melinta.com

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

Talent4Boards Team

here the original post =>